Consumer views on the use of digital tools for reporting adverse drug reactions: a cross-sectional study

被引：0
作者：
Dedefo, Mohammed Gebre [1 ]
Lim, Renly [1 ]
Kassie, Gizat M. [1 ]
Gebreyohannes, Eyob Alemayehu [1 ]
Salekdeh, Nava Nikpay [2 ]
Roughead, Elizabeth [1 ]
Kalisch Ellett, Lisa [1 ]
机构：
[1] Univ South Australia, Qual Use Med & Pharm Res Ctr, UniSA Clin & Hlth Sci, Adelaide, Australia
[2] Univ South Australia, UniSA Clin & Hlth Sci, Adelaide, Australia
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2025年 / 47卷 / 02期
关键词：
Adverse drug reaction reporting systems; Consumer behavior; Digital technology; Drug-related side effects and adverse reactions; Mobile applications; Pharmacovigilance; HEALTH-CARE PROFESSIONALS; MOBILE APP; INFORMATION; TECHNOLOGY; ACCEPTANCE; MOTIVES;
D O I：
10.1007/s11096-024-01847-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
BackgroundThe application of digital technologies has shown benefits in enhancing pharmacovigilance activities but consumers views on the use of these tools for this purpose are not well described. AimTo explore consumers' views on using digital tools to report adverse drug reactions (ADRs) and identify key features that consumers want in digital tools for ADR reporting. MethodAn online survey was conducted among adults who had taken medicine in the previous six-months in Australia. The development of questions was guided by the Combined Technology Acceptance Model and Theory of Planned Behaviour (C-TAM-TPB) framework. Responses to closed-ended questions were analysed using descriptive statistics and chi-square/Fisher's exact test, while free-text responses were analysed using qualitative content analysis. ResultsA total of 494 responses were included in the analysis. Eighty-seven percent of respondents preferred using digital tools for reporting ADRs. Consumers indicated a free-text space for describing ADRs (90%) as important or very important features of digital tools for ADR reporting, followed by acknowledgement of their report submission (87%) and receiving summary of previously reported ADRs (87%). Women (p < 0.001), advanced smartphone users (p < 0.001), and previous digital healthcare tool users (p = 0.017) showed higher intention to use digital tools. Consumers emphasized the importance of ease-of-use, accessibility, receiving medicine safety information, feedback, and advice for reporting ADRs via digital tools. ConclusionConsumers prefer using digital tools for reporting ADRs and place high value on features such as a free-text space for describing ADRs, acknowledgement of report submissions, and access to summaries of previously submitted reports.
引用
收藏
页码：423 / 434
页数：12
相关论文
共 47 条
  • [1] The importance of pharmacovigilance, safety monitoring of medicinal products.
  • [2] Khalil H., Huang C., Adverse drug reactions in primary care: a scoping review, BMC Health Serv Res, (2020)
  • [3] Sultana J., Cutroneo P., Trifiro G., Clinical and economic burden of adverse drug reactions, J Pharmacol Pharmacother, 4, pp. S73-S77, (2013)
  • [4] Coleman J.J., Pontefract S.K., Adverse drug reactions, Clin Med, 16, 5, pp. 481-485, (2016)
  • [5] Waller P.C., Making the most of spontaneous adverse drug reaction reporting, Basic Clin Pharmacol Toxicol, 98, 3, pp. 320-323, (2006)
  • [6] Alomar M., Tawfiq A.M., Hassan N., Et al., Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future, Ther Adv Drug Saf, (2020)
  • [7] Clark J.A., Klincewicz S.L., Stang P.E., Spontaneous adverse event signaling methods: classification and use with health care treatment products, Epidemiol Rev, 23, 2, pp. 191-210, (2001)
  • [8] Hazell L., Shakir S.A.W., Under-reporting of adverse drug reactions: a systematic review, Drug Saf, 29, 5, pp. 385-396, (2006)
  • [9] Lopez-Gonzalez E., Herdeiro M.T., Figueiras A., Determinants of under-reporting of adverse drug reactions: a systematic review, Drug Saf, 32, 1, pp. 19-31, (2009)
  • [10] Steurbaut S., Hanssens Y., Pharmacovigilance: empowering healthcare professionals and patients, Int J Clin Pharm, 36, pp. 859-862, (2014)
12345